Caplin, Martyn E <br/><br/>
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.  [electronic resource] 

 -  The New England journal of medicine  Jul 2014 
 - 224-33 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa1316158  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Delayed-Action Preparations<br/>Diarrhea--etiology<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Female<br/>Gastrointestinal Neoplasms--drug therapy<br/>Humans<br/>Male<br/>Middle Aged<br/>Neuroendocrine Tumors--drug therapy<br/>Pancreatic Neoplasms--drug therapy<br/>Peptides, Cyclic--adverse effects<br/>Somatostatin--adverse effects